Based on it being an MMP-9 inhibitor and microglial activation blocker (81), the tetracycline antibiotic minocycline has been proposed for the treatment of depressive symptoms as well as negative symptoms in schizophrenia (82–84). This evidence concerns the gene MMP9 and schizophrenia.